Valtropin Is The Second Biosimilar Product Approved In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopartners’ somatropin is a follow-on to Pfizer’s Genotropin.
You may also be interested in...
EMEA Denies Biosimilar To Roche’s Interferon Alfa-2a
BioPartners’ Alpheon – a generic version of Roferon-A – has “major quality concerns,” the European Medicines Agency finds.
EMEA Denies Biosimilar To Roche’s Interferon Alfa-2a
BioPartners’ Alpheon – a generic version of Roferon-A – has “major quality concerns,” the European Medicines Agency finds.
Omnitrope Gains Final EU Approval
Sandoz will launch the Genotropin follow-on in Germany and Austria in the coming days.